11th Nov 2016 08:01
For immediate release | 11 November 2016 |
This announcement contains inside information
Quantum Pharma Plc
('Quantum' or the 'Company')
Director's Dealings
Quantum Pharma Plc (AIM: QP.) the service-led niche pharmaceutical developer, manufacturer and supplier to the health and care sectors, announces that, following admission earlier today of the 44,117,647 ordinary shares of £0.10 each ('Ordinary Shares') in connection with the placing announced on 20 October 2016 (the 'Placing') the following dealings by Directors in the Company's Ordinary Shares, by way of their participation in the Placing, have now taken place at the placing price of 34 pence per Ordinary Share.
Following these dealings, their resulting interests are as follows:
Director | Ordinary Shares held prior to dealing | Ordinary Shares purchased in the Placing | Ordinary Shares held post dealing | % interest in issued ordinary share capital | Interest in Ordinary Shares via incentive arrangements (unvested) | Total % interest in issued ordinary share capital |
Chris Rigg | 15,000 | 147,059 | 162,059 | 0.10 | 696,281 | 0.51 |
Ian Johnson | - | 58,824 | 58,824 | 0.03 | - | 0.03 |
Dr. John Brown | - | 73,529 | 73,529 | 0.04 | - | 0.04 |
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Chris Rigg | ||||
2 | Reason for the notification | |||||
a) | Position/status | CEO and CFO | ||||
b)
| Initial notification /Amendment | Initial notification | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Quantum Pharma Plc | ||||
b) | LEI | (Pending) | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a)
| Description of the financial instrument, type of instrument Identification code | Ordinary shares of £0.10
ISIN: GB00BRTL8Q42 | ||||
b) | Nature of the transaction | Purchase of Ordinary Shares | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information - Aggregated volume - Price | N/A - single transaction | ||||
e) | Date of the transaction | 11 November 2016 | ||||
f) | Place of the transaction | London Stock Exchange, AIM | ||||
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Ian Johnson | ||||
2 | Reason for the notification | |||||
a) | Position/status | Non-Executive Chairman | ||||
b)
| Initial notification /Amendment | Initial notification | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Quantum Pharma Plc | ||||
b) | LEI | (Pending) | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a)
| Description of the financial instrument, type of instrument Identification code | Ordinary shares of £0.10
ISIN: GB00BRTL8Q42 | ||||
b) | Nature of the transaction | Purchase of Ordinary Shares | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information - Aggregated volume - Price | N/A - single transaction | ||||
e) | Date of the transaction | 11 November 2016 | ||||
f) | Place of the transaction | London Stock Exchange, AIM | ||||
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Dr John Brown |
2 | Reason for the notification | |
a) | Position/status | Non-Executive Director |
b)
| Initial notification /Amendment | Initial notification |
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Quantum Pharma Plc |
b) | LEI | (Pending) |
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a)
| Description of the financial instrument, type of instrument Identification code | Ordinary shares of £0.10
ISIN: GB00BRTL8Q42 |
b) | Nature of the transaction | Purchase of Ordinary Shares |
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information - Aggregated volume - Price | N/A - single transaction | ||||
e) | Date of the transaction | 11 November 2016 | ||||
f) | Place of the transaction | London Stock Exchange, AIM |
- Ends -
For further information:
Quantum Pharma Plc | |||
Ian Johnson, Chairman Chris Rigg, CEO and CFO Craig Swinhoe, Group Strategic Projects Director and Company Secretary | Tel: +44 (0) 1207 279 404 www.quantumpharmaplc.com | ||
Zeus Capital Limited (Nominated Adviser & Joint Broker) |
Tel: +44 (0) 20 3829 5000 | ||
Andrew Jones / Nick Cowles / Jamie Peel | www.zeuscapital.co.uk | ||
Dominic Wilson / Adam Pollock / John Goold | |||
N+1 Singer (Joint Broker) Aubrey Powell / James White / Sandy Ritchie Nick Owen / Brough Ransom
|
Tel: +44 (0) 20 7496 3000 www.n1singer.com
| ||
Media enquiries: | |||
Buchanan | |||
Henry Harrison-Topham / Sophie Cowles / Steph Watson | Tel: +44 (0) 20 7466 5000 | ||
www.buchanan.uk.com | |||
Notes to Editors
Quantum Pharma Plc is a service-led, niche pharmaceutical developer, manufacturer and supplier to the retail pharmacy, pharmaceutical wholesaler, hospital, homecare and care home markets. Quantum Pharma operates through three divisions: Specials, Niche Pharmaceuticals and Medication Adherence, offering a portfolio of innovative and complementary products and services.
Specials comprises three business units (Quantum Pharmaceutical, UL Medicines and Quantum Aseptics Services). This division manufactures, procures and supplies bespoke specials; batch made specials; aseptically prepared sterile intravenous medicines; imported medicines and special obtain products in response to a request from a prescriber for a bespoke medicine or special product to optimise patient treatment. The division offers an unrivalled and constantly expanding range of products. It has a customer-focused, service-driven business model, which provides shorter lead times than any of its competitors.
Niche Pharmaceuticals comprises three business units (Colonis, Lamda and PERN Consumer Products). This division is a product development and commercialisation business focusing on taking niche drugs through the regulatory pathway to achieve regulated status (licensed product or medical device). The division uses the excellent visibility of trends in the UK pharmacy and hospital markets gained through our Specials and Medication Adherence divisions, to allow early identification of the market opportunity to take products from unlicensed to licensed status. The division has a growing portfolio and pipeline of products that fit this unlicensed to licensed pathway, as well as complementary generic, generic plus or medical devices intended to meet unmet patient needs across a number of therapeutic areas.
Medication Adherence comprises two business units (Biodose® and Biodose Services®). This division provides products and services to enhance the likelihood of a patient adhering to a medication regime, patient-focused homecare services and services to pharmaceutical companies. It owns Biodose®, the only medication delivery system on the market that accommodates both liquid and solid doses. Biodose Connect™ takes patient safety and adherence to the next level by enabling remote monitoring of adherence to medication regimes. The division also operates a range of specialist patient-focused homecare services to the NHS, private clinics and pharmaceutical companies and provides the Group with exposure to the homecare and supported living sectors of the care pathway, complementing the focus of the remainder of the Group.
For further information, please visit www.quantumpharmaplc.com.
Related Shares:
Quantum Pharma